Enigmas of IDH mutations in hematology/oncology

Experimental Hematology

Volumn 43, Issue 8, 2015, Pages 685-697

  Heuser, Michael ^a   Maria Araujo Cruz, Michelle ^a   Goparaju, Ramya ^a   Chaturvedi, Anuhar ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYGLUTARIC ACID; AGI 6780; AZACITIDINE; DECITABINE; HOMEODOMAIN PROTEIN; HYPOXIA INDUCIBLE FACTOR; ISOCITRATE DEHYDROGENASE; OXIDOREDUCTASE INHIBITOR; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VENETOCLAX; WNT PROTEIN; ALPHA-HYDROXYGLUTARATE; ENZYME INHIBITOR; GLUTARIC ACID DERIVATIVE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ASTROCYTOMA; BILE DUCT CARCINOMA; CANCER GRADING; CARCINOGENESIS; CAUSAL ATTRIBUTION; CHRONIC MYELOMONOCYTIC LEUKEMIA; DNA METHYLATION; DRUG EFFICACY; DRUG TARGETING; ENANTIOMER; ENZYME INHIBITION; GENE EXPRESSION; GENE FREQUENCY; GENE IDENTIFICATION; GENE LOCATION; GLIOBLASTOMA; HEMATOLOGIC MALIGNANCY; HUMAN; HYDROXYGLUTARIC ACIDURIA; IDH GENE; IDH1 GENE; IDH2 GENE; METABOLIC DISORDER; MUTATIONAL ANALYSIS; MYELODYSPLASTIC SYNDROME; MYELOID METAPLASIA; NONHUMAN; ONCOGENE; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROSTATE CARCINOMA; REVIEW; SIGNAL TRANSDUCTION; T CELL LYMPHOMA; THROMBOCYTOPENIA; TUMOR DIFFERENTIATION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; ENZYMOLOGY; GENETICS; HEMATOLOGIC NEOPLASMS; METABOLISM; MUTATION; STEREOISOMERISM;

ANIMALS; DNA METHYLATION; ENZYME INHIBITORS; GLUTARATES; HEMATOLOGIC NEOPLASMS; HUMANS; ISOCITRATE DEHYDROGENASE; MUTATION; STEREOISOMERISM;

EID: 84939265909     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2015.05.005     Document Type: Review

References (115)

1. Hausinger R.P. FeII/alpha-ketoglutarate-dependent hydroxylases and related enzymes. Crit Rev Biochem Mol Biol 2004, 39:21-68.
2. Jo S.H., Lee S.H., Chun H.S., et al. Cellular defense against UVB-induced phototoxicity by cytosolic NADP(+)-dependent isocitrate dehydrogenase. Biochem Biophys Res Commun 2002, 292:542-549.
3. Kim S.Y., Lee S.M., Tak J.K., Choi K.S., Kwon T.K., Park J.W. Regulation of singlet oxygen-induced apoptosis by cytosolic NADP+-dependent isocitrate dehydrogenase. Mol Cell Biochem 2007, 302:27-34.
4. Koh H.J., Lee S.M., Son B.G., et al. Cytosolic NADP+-dependent isocitrate dehydrogenase plays a key role in lipid metabolism. J Biol Chem 2004, 279:39968-39974.
5. Filipp F.V., Scott D.A., Ronai Z.A., Osterman A.L., Smith J.W. Reverse TCA cycle flux through isocitrate dehydrogenases 1 and 2 is required for lipogenesis in hypoxic melanoma cells. Pigment Cell Melanoma Res 2012, 25:375-383.
6. Thol F., Damm F., Wagner K., et al. Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. Blood 2010, 116:614-616.
7. Wagner K., Damm F., Gohring G., et al. Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. J Clin Oncol 2010, 28:2356-2364.
8. Paschka P., Schlenk R.F., Gaidzik V.I., et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 2010, 28:3636-3643.
9. Dang L., White D.W., Gross S., et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2010, 465:966.
10. Gross S., Cairns R.A., Minden M.D., et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med 2010, 207:339-344.
11. Ward P.S., Patel J., Wise D.R., et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010, 17:225-234.
12. Zhao S., Lin Y., Xu W., et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 2009, 324:261-265.
13. Marcucci G., Maharry K., Wu Y.Z., et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study. J Clin Oncol 2010, 28:2348-2355.
14. Parsons D.W., Jones S., Zhang X., et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321:1807-1812.
15. Balss J., Meyer J., Mueller W., Korshunov A., Hartmann C., von Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 2008, 116:597-602.
16. Bleeker F.E., Lamba S., Leenstra S., et al. IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat 2009, 30:7-11.
17. Dubbink H.J., Taal W., van Marion R., et al. IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. Neurology 2009, 73:1792-1795.
18. Hartmann C., Meyer J., Balss J., et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: A study of 1,010 diffuse gliomas. Acta Neuropathol 2009, 118:469-474.
19. Ichimura K., Pearson D.M., Kocialkowski S., et al. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol 2009, 11:341-347.
20. Kang M.R., Kim M.S., Oh J.E., et al. Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int J Cancer 2009, 125:353-355.
21. Nobusawa S., Watanabe T., Kleihues P., Ohgaki H. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 2009, 15:6002-6007.
22. Watanabe T., Nobusawa S., Kleihues P., Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 2009, 174:1149-1153.
23. Yan H., Parsons D.W., Jin G., et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009, 360:765-773.
24. Hartmann C., Hentschel B., Wick W., et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: Implications for classification of gliomas. Acta Neuropathol 2010, 120:707-718.
25. Mardis E.R., Ding L., Dooling D.J., et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009, 361:1058-1066.
26. Abbas S., Lugthart S., Kavelaars F.G., et al. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: Prevalence and prognostic value. Blood 2010, 116:2122-2126.
27. Green A., Beer P. Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. N Engl J Med 2010, 362:369-370.
28. Ho P.A., Alonzo T.A., Kopecky K.J., et al. Molecular alterations of the IDH1 gene in AML: A Children's Oncology Group and Southwest Oncology Group study. Leukemia 2010, 24:909-913.
29. Schnittger S., Haferlach C., Ulke M., Alpermann T., Kern W., Haferlach T. IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status. Blood 2010, 116:5486-5496.
30. Andersson A.K., Miller D.W., Lynch J.A., et al. IDH1 and IDH2 mutations in pediatric acute leukemia. Leukemia 2011, 25:1570-1577.
31. Damm F., Thol F., Hollink I., et al. Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: A study of the AML-BFM and DCOG study groups. Leukemia 2011, 25:1704-1710.
32. Patel K.P., Ravandi F., Ma D., et al. Acute myeloid leukemia with IDH1 or IDH2 mutation: Frequency and clinicopathologic features. Am J Clin Pathol 2011, 135:35-45.
33. Ibanez M., Such E., Cervera J., et al. Screening for IDH mutations in chronic myelomonocytic leukemia. Leuk Lymphoma 2013, 54:406-407.
34. Kosmider O., Gelsi-Boyer V., Slama L., et al. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia 2010, 24:1094-1096.
35. Pardanani A., Lasho T.L., Finke C.M., Mai M., McClure R.F., Tefferi A. IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms. Leukemia 2010, 24:1146-1151.
36. Pardanani A., Patnaik M.M., Lasho T.L., et al. Recurrent IDH mutations in high-risk myelodysplastic syndrome or acute myeloid leukemia with isolated del(5q). Leukemia 2010, 24:1370-1372.
37. Tefferi A., Lasho T.L., Abdel-Wahab O., et al. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia 2010, 24:1302-1309.
38. Thol F., Weissinger E.M., Krauter J., et al. IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica 2010, 95:1668-1674.
39. Lopez G.Y., Reitman Z.J., Solomon D., et al. IDH1(R132) mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain. Biochem Biophys Res Commun 2010, 398:585-587.
40. Amary M.F., Bacsi K., Maggiani F., et al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol 2011, 224:334-343.
41. Yoshida K., Sanada M., Ogawa S. [IDH1/2 gene mutations in myelodysplastic syndromes]. Rinsho Ketsueki 2012, 53:391-395.
42. Jeziskova I., Razga F., Bajerova M., Racil Z., Mayer J., Dvorakova D. IDH2 mutations in patients with acute myeloid leukemia: Missense p.R140 mutations are linked to disease status. Leuk Lymphoma 2010, 51:2285-2287.
43. Boissel N., Nibourel O., Renneville A., Huchette P., Dombret H., Preudhomme C. Differential prognosis impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. Blood 2011, 117:3696-3697.
44. Green C.L., Evans C.M., Zhao L., et al. The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. Blood 2011, 118:409-412.
45. Ho P.A., Kutny M.A., Alonzo T.A., et al. Leukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: A report from the Children's Oncology Group. Pediatr Blood Cancer 2011, 57:204-209.
46. Cairns R.A., Iqbal J., Lemonnier F., et al. IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood 2012, 119:1901-1903.
47. Pansuriya T.C., van Eijk R., d'Adamo P., et al. Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. Nat Genet 2011, 43:1256-1261.
48. Borger D.R., Tanabe K.K., Fan K.C., et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist 2012, 17:72-79.
49. Heuser M., Yun H., Berg T., et al. Cell of origin in AML: Susceptibility to MN1-induced transformation is regulated by the MEIS1/AbdB-like HOX protein complex. Cancer Cell 2011, 20:39-52.
50. Verhaak R.G., Goudswaard C.S., van Putten W., et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): Association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood 2005, 106:3747-3754.
51. Krivtsov A.V., Armstrong S.A. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer 2007, 7:823-833.
52. Kim Y.H., Nobusawa S., Mittelbronn M., et al. Molecular classification of low-grade diffuse gliomas. Am J Pathol 2010, 177:2708-2714.
53. Bettegowda C., Agrawal N., Jiao Y., et al. Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science 2011, 333:1453-1455.
54. Jimenez G., Guichet A., Ephrussi A., Casanova J. Relief of gene repression by torso RTK signaling: Role of capicua in Drosophila terminal and dorsoventral patterning. Genes Dev 2000, 14:224-231.
55. Astigarraga S., Grossman R., Diaz-Delfin J., Caelles C., Paroush Z., Jimenez G. A MAPK docking site is critical for downregulation of Capicua by Torso and EGFR RTK signaling. EMBO J 2007, 26:668-677.
56. Wakimoto H., Tanaka S., Curry W.T., et al. Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas. Clin Cancer Res 2014, 20:2898-2909.
57. Broderick D.K., Di C., Parrett T.J., et al. Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res 2004, 64:5048-5050.
58. MacDonald T.J., Brown K.M., LaFleur B., et al. Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nat Genet 2001, 29:143-152.
59. Zhang H., Bajraszewski N., Wu E., et al. PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J Clin Invest 2007, 117:730-738.
60. Engelman J.A., Chen L., Tan X., et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008, 14:1351-1356.
61. Organ S.L., Tsao M.S. An overview of the c-MET signaling pathway. Ther Adv Med Oncol 2011, 3:S7-S19.
62. Chaturvedi A., Araujo Cruz M.M., Jyotsana N., et al. Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML. Blood 2013, 122:2877-2887.
63. Kats L.M., Reschke M., Taulli R., et al. Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance. Cell Stem Cell 2014, 14:329-341.
64. Chen C., Liu Y., Lu C., et al. Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition. Genes Dev 2013, 27:1974-1985.
65. Saha S.K., Parachoniak C.A., Ghanta K.S., et al. Mutant IDH inhibits HNF-4alpha to block hepatocyte differentiation and promote biliary cancer. Nature 2014, 513:110-114.
66. Esmaeili M., Hamans B.C., Navis A.C., et al. IDH1 R132H mutation generates a distinct phospholipid metabolite profile in glioma. Cancer Res 2014, 74:4898-4907.
67. DiNardo C.D., Propert K.J., Loren A.W., et al. Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. Blood 2013, 121:4917-4924.
68. Fathi A.T., Sadrzadeh H., Borger D.R., et al. Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response. Blood 2012, 120:4649-4652.
69. Wang J.H., Chen W.L., Li J.M., et al. Prognostic significance of 2-hydroxyglutarate levels in acute myeloid leukemia in China. Proc Natl Acad Sci U S A 2013, 110:17017-17022.
70. Capper D., Simon M., Langhans C.D., et al. 2-Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size. Int J Cancer 2012, 131:766-768.
71. Ward P.S., Cross J.R., Lu C., et al. Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production. Oncogene 2012, 31:2491-2498.
72. Shim E.H., Livi C.B., Rakheja D., et al. L-2-Hydroxyglutarate: An epigenetic modifier and putative oncometabolite in renal cancer. Cancer Discov 2014, 4:1290-1298.
73. Kranendijk M., Struys E.A., Salomons G.S., Van der Knaap M.S., Jakobs C. Progress in understanding 2-hydroxyglutaric acidurias. J Inherit Metab Dis 2012, 35:571-587.
74. Nota B., Struys E.A., Pop A., et al. Deficiency in SLC25A1, encoding the mitochondrial citrate carrier, causes combined D-2- and L-2-hydroxyglutaric aciduria. Am J Hum Genet 2013, 92:627-631.
75. Larnaout A., Amouri R., Neji S., Zouari M., Kaabachi N., Hentati F. Osteoma of the calvaria in L-2-hydroxyglutaric aciduria. J Inherit Metab Dis 2007, 30:980.
76. Rakheja D., Mitui M., Boriack R.L., DeBerardinis R.J. Isocitrate dehydrogenase 1/2 mutational analyses and 2-hydroxyglutarate measurements in Wilms tumors. Pediatr Blood Cancer 2011, 56:379-383.
77. Sasaki M., Knobbe C.B., Munger J.C., et al. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature 2012, 488:656-659.
78. Sasaki M., Knobbe C.B., Itsumi M., et al. D-2-Hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function. Genes Dev 2012, 26:2038-2049.
79. Chaturvedi A., Araujo Cruz M.M., Jyotsana N., et al. The metabolite R-2-hydroxyglutarate (R2HG) collaborates with HoxA9 to induce monocytic leukemia. Blood 2014, 124:366.
80. Losman J.A., Looper R.E., Koivunen P., et al. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science 2013, 339:1621-1625.
81. Rose N.R., McDonough M.A., King O.N., Kawamura A., Schofield C.J. Inhibition of 2-oxoglutarate dependent oxygenases. Chem Soc Rev 2011, 40:4364-4397.
82. Loenarz C., Schofield C.J. Expanding chemical biology of 2-oxoglutarate oxygenases. Nat Chem Biol 2008, 4:152-156.
83. Xu W., Yang H., Liu Y., et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 2011, 19:17-30.
84. Koivunen P., Lee S., Duncan C.G., et al. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature 2012, 483:484-488.
85. Hirata M., Sasaki M., Cairns R.A., et al. Mutant IDH is sufficient to initiate enchondromatosis in mice. Proc Natl Acad Sci U S A 2015, 112:2829-2834.
86. Chan S.M., Thomas D., Corces-Zimmerman M.R., et al. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat Med 2015, 21:178-184.
87. Lu C., Ward P.S., Kapoor G.S., et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012, 483:474-478.
88. Kernytsky A., Wang F., Hansen E., et al. IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition. Blood 2015, 125:296-303.
89. Chowdhury R., Yeoh K.K., Tian Y.M., et al. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep 2011, 12:463-469.
90. Agger K., Christensen J., Cloos P.A., Helin K. The emerging functions of histone demethylases. Curr Opin Genet Dev 2008, 18:159-168.
91. Duncan T., Trewick S.C., Koivisto P., Bates P.A., Lindahl T., Sedgwick B. Reversal of DNA alkylation damage by two human dioxygenases. Proc Natl Acad Sci U S A 2002, 99:16660-16665.
92. Noushmehr H., Weisenberger D.J., Diefes K., et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010, 17:510-522.
93. Figueroa M.E., Abdel-Wahab O., Lu C., et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010, 18:553-567.
94. Ko M., Huang Y., Jankowska A.M., et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 2010, 468:839-843.
95. Rohle D., Popovici-Muller J., Palaskas N., et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 2013, 340:626-630.
96. Borodovsky A., Salmasi V., Turcan S., et al. 5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft. Oncotarget 2013, 4:1737-1747.
97. Wang F., Travins J., DeLaBarre B., et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science 2013, 340:622-626.
98. Stein A.M., Altman K.J., Collins R., et al. AG-221, an oral, selective, first-in-class, potent inhibitor of the IDH2 mutant metabolic enzyme, induces durable remissions in a phase I study in patients with IDH2 mutation positive advanced hematologic malignancies. Blood 2014, 124:115.
99. Turcan S., Rohle D., Goenka A., et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2012, 483:479-483.
100. Guilhamon P., Eskandarpour M., Halai D., et al. Meta-analysis of IDH-mutant cancers identifies EBF1 as an interaction partner for TET2. Nat Commun 2013, 4:2166.
101. Reitman Z.J., Sinenko S.A., Spana E.P., Yan H. Genetic dissection of leukemia-associated IDH1 and IDH2 mutants and D-2-hydroxyglutarate in Drosophila. Blood 2015, 125:336-345.
102. 2-regulated prolyl hydroxylation. Science 2001, 292:468-472.
103. Jaakkola P.M., Rantanen K. The regulation, localization, and functions of oxygen-sensing prolyl hydroxylase PHD3. Biol Chem 2013, 394:449-457.
104. Lipscomb E.A., Sarmiere P.D., Crowder R.J., Freeman R.S. Expression of the SM-20 gene promotes death in nerve growth factor-dependent sympathetic neurons. J Neurochem 1999, 73:429-432.
105. Hogel H., Rantanen K., Jokilehto T., Grenman R., Jaakkola P.M. Prolyl hydroxylase PHD3 enhances the hypoxic survival and G1 to S transition of carcinoma cells. PLoS One 2011, 6:e27112.
106. Guitart A.V., Subramani C., Armesilla-Diaz A., et al. Hif-2alpha is not essential for cell-autonomous hematopoietic stem cell maintenance. Blood 2013, 122:1741-1745.
107. Rouault-Pierre K., Lopez-Onieva L., Foster K., et al. HIF-2alpha protects human hematopoietic stem/progenitors and acute myeloid leukemic cells from apoptosis induced by endoplasmic reticulum stress. Cell Stem Cell 2013, 13:549-563.
108. Wang Y., Liu Y., Malek S.N., Zheng P. Targeting HIF1alpha eliminates cancer stem cells in hematological malignancies. Cell Stem Cell 2011, 8:399-411.
109. Fu Y., Zheng Y., Li K., et al. Mutations in isocitrate dehydrogenase 2 accelerate glioma cell migration via matrix metalloproteinase-2 and 9. Biotechnol Lett 2012, 34:441-446.
110. Williams S.C., Karajannis M.A., Chiriboga L., Golfinos J.G., von Deimling A., Zagzag D. R132H-mutation of isocitrate dehydrogenase-1 is not sufficient for HIF-1alpha upregulation in adult glioma. Acta Neuropathol 2011, 121:279-281.
111. Mahon P.C., Hirota K., Semenza G.L. FIH-1: A novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev 2001, 15:2675-2686.
112. Lando D., Peet D.J., Gorman J.J., Whelan D.A., Whitelaw M.L., Bruick R.K. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev 2002, 16:1466-1471.
113. Tarhonskaya H., Rydzik A.M., Leung I.K., et al. Non-enzymatic chemistry enables 2-hydroxyglutarate-mediated activation of 2-oxoglutarate oxygenases. Nat Commun 2014, 5:3423.
114. Konopleva M., Pollyea D.A., Potluri J., et al. A Phase 2 Study of ABT-199 (GDC-0199) in Patients with Acute Myelogenous Leukemia (AML). Blood 2014, 124:118.
115. Rzem R., Vincent M.F., Van Schaftingen E., Veiga-da-Cunha M. L-2-Hydroxyglutaric aciduria, a defect of metabolite repair. J Inherit Metab Dis 2007, 30:681-689.